Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 10/30/2008) - Treatment with a radiolabeled monoclonal antibody appears to be highly effective as consolidation after first-line therapy in patients with indolent, advanced-stage follicular lymphoma, according to the October 14, 2008, Journal of Clinical Oncology.
Drug Combination Cuts Risk of Advanced Colon Polyps
(Posted: 04/21/2008, Updated: 10/19/2008) - Low doses of two chemopreventive agents are highly effective at preventing the recurrence of the lesions that are often precursors to colorectal cancer, according to results presented at the 2008 American Association for Cancer Research annual meeting.
Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
(Posted: 09/17/2008) - Computerized tomographic colonography, also known as virtual colonoscopy, is comparable to standard colonoscopy, which uses a long, flexible tube with a camera to view the lining of the colon, in its ability to accurately detect cancer and precancerous polyps and could serve as an initial screening exam for colorectal cancer, according to the results of the American College of Radiology Imaging Network National CT Colonography Trial.
Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 01/09/2007, Updated: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Updated: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.